Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
- PMID: 33533142
- PMCID: PMC8410541
- DOI: 10.1002/1878-0261.12921
Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
Abstract
Myeloid neoplasms (MN) with germline predisposition (MNGP) are likely to be more common than currently appreciated. Many of the genes involved in MNGP are also recurrently mutated in sporadic MN. Therefore, routine analysis of gene panels by next-generation sequencing provides an effective approach to detect germline variants with clinical significance in patients with hematological malignancies. Gene panel sequencing was performed in 88 consecutive and five nonconsecutive patients with MN diagnosis. Disease-causing germline mutations in CEBPα, ASXL1, TP53, MPL, GATA2, DDX41, and ETV6 genes were identified in nine patients. Six out of the nine patients with germline variants had a strong family history. These patients presented great heterogeneity in the age of diagnosis and phenotypic characteristics. In our study, there were families in which all the affected members presented the same subtype of disease, whereas members of other families presented various disease phenotypes. This intrafamiliar heterogeneity suggests that the acquisition of particular somatic variants may drive the evolution of the disease. This approach enabled high-throughput detection of MNGP in patients with MN diagnosis, which is of great relevance for both the patients themselves and the asymptomatic mutation carriers within the family. It is crucial to make a proper diagnosis of these patients to provide them with the most suitable treatment, follow-up, and genetic counseling.
Keywords: family history; genetic counseling; hereditary cancer; myeloid neoplasms with germline predisposition; next-generation sequencing.
© 2021 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Guidugli L, Johnson AK, Alkorta‐Aranburu G, Nelakuditi V, Arndt K, Churpek JE, Godley LA, Townsley D, Young NS, Fitzpatrick Cet al. (2017) Clinical utility of gene panel‐based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia 31, 1226–1229. - PMC - PubMed
-
- Pippucci T, Savoia A, Perrotta S, Pujol‐Moix N, Noris P, Castegnaro G, Pecci A, Gnan C, Punzo F, Marconi Cet al. (2011) Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal‐dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 88, 115–120. - PMC - PubMed
-
- Schlegelberger B & Heller PG (2017) RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol 54, 75–80. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
